Could a prostate cancer drug help fight kidney cancer?
NCT ID NCT06222593
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding bicalutamide (a prostate cancer drug) to sunitinib (a standard kidney cancer drug) can help people whose kidney cancer has stopped responding to other targeted therapies. The trial will enroll 28 adults with advanced renal cell carcinoma. Researchers will check for side effects and measure if tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bicalutamide and sunitinib
What this could lead to
If it works, this could offer a new treatment option for people with advanced kidney cancer that no longer responds to standard targeted therapy.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UB/ Great Lakes Cancer Care
RECRUITINGBuffalo, New York, 14203, United States